Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2020-03-17 Director's Dealing
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document begins with an 'RNS Number' and explicitly states it is a notification regarding a 'Director/PDMR Shareholding' involving the purchase of ordinary shares by a Non-Executive Director, Alan Mawson. This content directly matches the definition of insider trading or director's dealing reports. The filing category 'Director's Dealing (Code: DIRS)' is the most appropriate classification. Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2020-03-17 English
Belfast investor presentation
Regulatory Filings Classification · 98% confidence The document is a regulatory announcement (indicated by the RNS Number and the closing statement referencing RNS and the London Stock Exchange). The core content announces that Fusion Antibodies plc will hold a presentation for investors on a future date (April 6, 2020). This is not the presentation itself, but an announcement about the event. The closest matching category for an announcement regarding an upcoming investor event or presentation is 'Investor Presentation' (IP). However, since this is a short regulatory filing announcing the *scheduling* of an investor presentation, and it is distributed via RNS, it could also be considered a general Regulatory Filing (RNS). Given the specific nature of the announcement (scheduling an 'investor presentation'), IP is a strong candidate. However, the definition for IP is 'Detailed presentation for investors focusing on financials, strategy, and market position.' This document is only the *announcement* of the presentation, not the presentation content itself. The definition for Report Publication Announcement (RPA) is 'Announcement regarding the timing, release, or publication of company reports'. While this is an announcement about an event, not a report, the content is highly specific to an investor meeting. Given the structure (RNS format, short length, announcing a future event), it functions as a general regulatory update. If the document *were* the presentation slides, IP would be correct. Since it is the announcement of the event, and it is distributed via RNS, RNS is the most appropriate fallback for an announcement that doesn't fit the RPA definition perfectly (which usually refers to financial reports). Let's re-evaluate the options: AGM-R (No, it's not the AGM itself), ER (No, not earnings), IP (No, it's the announcement, not the presentation). The document explicitly details the schedule and logistics for an upcoming investor presentation. This is a common type of announcement. Since there isn't a specific code for 'Announcement of Investor Presentation', and it is a formal regulatory release (RNS), RNS is the safest general classification. However, if we interpret 'Investor Presentation' (IP) broadly to include announcements about them, it might fit. Given the strong focus on the upcoming investor event, and the fact that it is not a standard financial report announcement (RPA), I will classify it as RNS, the general regulatory filing category for such notices, as it is primarily an RNS release detailing logistics.
2020-02-17 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is clearly identified as an 'RNS Number' announcement from the London Stock Exchange. The content details a 'Director/PDMR Shareholding' transaction, specifically the sale of shares by the Chief Technical Officer, Richard Buick. This type of mandatory disclosure regarding insider transactions falls under regulatory reporting. While 'Director's Dealing' (DIRS) is a specific category, the document format (RNS) and the nature of mandatory regulatory disclosure often lead to classification as a general Regulatory Filing (RNS) if DIRS is not the primary focus or if the filing is a standard regulatory notification format. However, since the core content is explicitly about a Director's dealing (insider trade), DIRS is the most specific and appropriate code. The document is a direct notification, not an announcement of a report (ruling 2 does not apply).
2020-02-03 English
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document is very short (1505 characters) and contains the header 'RNS Number : 4884B'. The content describes a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. This type of immediate, short-form market operational announcement, especially one explicitly labeled with an RNS number and referencing the LSE's news service, fits best under the general Regulatory Filings category, as it is not a specific financial report, management change, or shareholder vote result. It is a general regulatory notice.
2020-01-30 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1488 characters) and contains the header 'RNS Number : 4873B'. It announces a 'Price Monitoring Extension' for a security, which is a specific, non-standard market operational announcement. It explicitly states that the information is provided by 'RNS, the news service of the London Stock Exchange' and that RNS is approved as a Primary Information Provider. This type of brief, operational market notice that doesn't fit into standard financial reporting categories (like 10-K, ER, or DIV) is best classified under the general regulatory announcement category, RNS.
2020-01-30 English
Trading update
Earnings Release Classification · 99% confidence The document is identified by the header 'RNS Number : 2227B' and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content is a 'Trading update' announcing that revenues for the year ending March 31, 2020, are expected to be significantly ahead of market expectations, along with commentary on gross profit margin and EBITDA outlook. This is a typical announcement of financial performance highlights for a period, but it is not the full comprehensive report (like 10-K or IR). Since it is a formal announcement disseminated via the London Stock Exchange's RNS system, and it provides key financial updates, it fits best under the general 'Regulatory Filings' category (RNS) as a specific announcement, or potentially an Earnings Release (ER) if it were quarterly, but RNS is the most accurate descriptor given the source identifier and format. Q3 2020
2020-01-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.